Pancreatic Cancer: Eight-Market Drug Forecast
Description
Pancreatic Cancer: Eight-Market Drug Forecast
Summary
This report covers the 8MM (US, France, Germany, Italy, Spain, UK, China, and Japan) and includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for Pancreatic cancer.
These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and POLI Price Intelligence databases.
Key Highlights
In the 8MM, the number of diagnosed incident cases of pancreatic cancer will grow from 229,166 cases in 2024 to 283,540 cases by 2034.
Common Pancreatic Cancer market drivers across the 8MM include -
Summary
This report covers the 8MM (US, France, Germany, Italy, Spain, UK, China, and Japan) and includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for Pancreatic cancer.
These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and POLI Price Intelligence databases.
Key Highlights
- Report deliverables include an Excel-based forecast model
- Forecasts includes the 8MM
- Forecasts covers from 2024-2034
- GlobalData valued the Pancreatic cancer market in the 8MM at $2.2 billion in 2024 and expects the market to increase to $10.2 billion by 2034
In the 8MM, the number of diagnosed incident cases of pancreatic cancer will grow from 229,166 cases in 2024 to 283,540 cases by 2034.
Common Pancreatic Cancer market drivers across the 8MM include -
- This market growth will be driven by the market entry of novel pipeline agents in both the established and unexplored patient segments, in addition to the active label expansion of marketed agents to cover patients with early disease.
- During the 2024 base year, chemotherapies contributed the most to the pancreatic cancer market. By the end of the forecast period, immune checkpoint inhibitors and immunostimulants are projected to account for nearly half of the total market share across the 8MM.
- Market entrance of bispecific antibodies and pan-KRAS inhibitor will have a significant impact on the treatment landscape.
- Across the 8MM, the metastatic first, second, and third lines of therapy are expected to experience the fastest growth in the forecast period at a CAGR of 15.5-26.6%, compared to the 2.5-3.6% CAGR in early-stage neoadjuvant and adjuvant therapy.
- Limited approved targeted therapy and poor clinical outcomes of immunotherapy are the two biggest obstacles for pancreatic cancer market growth.
- Many patients are diagnosed with advanced disease, and due to poor performance, do not reach beyond first-line therapy.
- Low patient population (BRCA1/2, PALB2, EGFR, MSI-H, NTRK, ROS1, KRAS, PD-1/PD-L1, and BRAF) is a major barrier to developing biomarker-based targeted therapy and market growth.
- The report provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends.
- Key topics covered include a strategic competitive assessment of current and future drugs, unmet needs, KOL insights, and implications for the Pancreatic Cancer market.
- The base year of the sales forecast model is 2024, and the forecast period is 2024-2034.
- Overview of Pancreatic cancer, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized Pancreatic cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Pancreatic cancer therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Pancreatic cancer treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
- Analysis of the current and future market competition in the global Pancreatic cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Pancreatic cancer therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Pancreatic cancer therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships
Table of Contents
- Abbreviations
- Related Reports
- Executive Summary
- Disease Overview
- Overview of Pancreatic Cancer
- Pancreatic Cancer Market Strength, Weakness, Opportunity, and Threat Analysis
- Epidemiology
- Diagnosed Incident Cases Both Sexes
- Age-Specific Diagnosed Incident Cases
- Sex-Specific Diagnosed Incident Cases
- Diagnosed Incident Cases by Type, Sex, Age
- Diagnosed Incident Cases by Stage at Diagnosis
- Diagnosed Incident Cases by Tumor Stage at Diagnosis
- Diagnosed Incident Cases of Stage Ta Pancreatic Cancer by Grade
- Diagnosed Incident Cases of Stage of Pancreatic Cancer by Broad Classification
- Diagnosed Incident Cases of Stage of NMIBC by Risk Group
- Diagnosed Incident Cases of Pancreatic Cancer by Mutations and Biomarkers
- Five-Year Diagnosed Prevalent Cases of Pancreatic Cancer
- Five-Year Diagnosed Prevalent Cases of Pancreatic Cancer by Tumor Stage
- Five-Year Diagnosed Prevalent Cases of Pancreatic Cancer by Broad Classification
- Five-Year Diagnosed Prevalent Cases of Pancreatic Cancer by Relapse or Recurrence
- Five-Year Diagnosed Prevalent Cases of Pancreatic Cancer by Treatment
- Disease Management
- Treatment Guidelines
- Treatment Paradigm - First-Line Therapy in Non-Muscle Invasive Pancreatic Cancer
- Treatment Paradigm - First-Line Therapy in Muscle Invasive Pancreatic Cancer
- Treatment Paradigm - Locally Advanced/Metastatic Pancreatic Cancer
- KOL Insight on the Pancreatic Cancer Treatment Algorithm
- Unmet Needs and Opportunities
- Unmet Needs in Pancreatic Cancer
- Competitive Landscape Assessment
- Pipeline Drugs Overview
- Competitive Landscape Methodology
- Competitive Assessment - Intravesical Delivered Therapies for NMIBC
- Competitive Assessment - Gene Therapies for NMIBC
- Competitive Assessment - Antibody-Drug Conjugates
- Market Outlook
- Pancreatic Cancer Market Forecast
- Pancreatic Cancer Market Forecast by Class
- Pancreatic Cancer Market Drivers and Barriers
- Appendix
- Primary Research: KOL Information
- Sources Used and Not Used to Forecast Diagnosed Incident Cases
- Sources Used to Forecast Diagnosed Incident Cases by Stage at Diagnosis
- Sources Used to Forecast Diagnosed Incident Cases by Tumor Stage at Diagnosis
- Sources Used to Forecast Diagnosed Incident Cases of Stage Ta Pancreatic Cancer by Grade
- Sources Used to Forecast Diagnosed Incident and Five-Year Diagnosed Prevalent Cases by Broad Classification
- Sources Used to Forecast Diagnosed Incident Cases of NMIBC by Risk Group
- Sources Used to Forecast Diagnosed Incident Cases by Mutations and Biomarkers
- Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases
- Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases by Relapse or Recurrence
- Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases by Treatment
- Sources and Methodology
- Epidemiological Forecast Insight
- Strengths and Limitations
- About the Authors
- Bibliography
- Contact Us
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
